Document:

EX-10.14

 Exhibit 10.14 

Execution Copy 

GENEXINE, INC. 
 AND

 TASGEN BIO-TECH (TIANJIN) CO., LTD. 

 
  

INTELLECTUAL PROPERTY ASSIGNMENT AND 

LICENSE AGREEMENT 
  

 
 DATED October 16th, 2015 

 Execution Copy 

 

 CONTENTS 
  

 

							
	ARTICLE	  	PAGE	 
			
	1.	 	DEFINITIONS	  	 	2	 
	2.	 	 ASSIGNMENT AND LICENSE OF INTELLECTUAL PROPERTIES
	  	 	3	 
	3.	 	 FEES AND ROYALTIES
	  	 	6	 
	4.	 	 TRAINING
	  	 	8	 
	5.	 	 JOINT DEVELOPMENT COMMITTEE.
	  	 	9	 
	6.	 	 IMPROVEMENTS
	  	 	9	 
	7.	 	 SALE OF PRODUCTS
	  	 	9	 
	8.	 	 BOOKS AND RECORDS
	  	 	10	 
	9.	 	 TAX
	  	 	10	 
	10.	 	 TECHNICAL DOCUMENTATION
	  	 	10	 
	11.	 	 MATERIALS
	  	 	11	 
	12.	 	 CONFIDENTIALITY
	  	 	11	 
	13.	 	 CLAIMS AND INFRINGEMENTS
	  	 	12	 
	14.	 	 REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	 	14	 
	15.	 	 TERM AND TERMINATION
	  	 	15	 
	16.	 	 INDEPENDENT CONTRACTORS
	  	 	17	 
	17.	 	 FORCE MAJEURE
	  	 	18	 
	18.	 	 LIABILITY FOR BREACH AND INDEMNIFICATION
	  	 	18	 
	19.	 	 SETTLEMENT OF DISPUTES
	  	 	19	 
	20.	 	 ASSIGNMENT
	  	 	19	 
	21.	 	 NOTICES
	  	 	19	 
	22.    	 	 MISCELLANEOUS
	  	 	20	 

 EXHIBIT A-1 LIST OF LICENSED INTELLECTUAL PROPERTIES 

EXHIBIT A-2 LIST OF ASSIGNED INTELLECTUAL PROPERTIES 

EXHIBIT B CONSENTS OF TECHNOLOGY TRANSFER 

  

 Execution Copy 

 

 INTELLECTUAL PROPERTY ASSIGNMENT AND 

LICENSE AGREEMENT 
 THIS
INTELLECTUAL PROPERTY ASSIGNMENT AND LICENSE AGREEMENT (the “Agreement”) is made on October 16th, 2015 

BETWEEN 
  

	(1)	 GENEXINE, INC., a limited liability company established in Korea, with its registered address at 700 Daewangpangyo-ro, Korea Bio-Park Bldg. B, Bundang-gu, Seongnam-si, Gyeonggi-do 463-400, Korea (“Genexine”); and 

  

	(2)	 TASGEN BIO-TECH (TIANJIN) CO., LTD., a limited liability company
established in Tianjin, the People’s Republic of China (the “PRC”), with its registered address at Chenhuan Building, Tianjin Pharma and Medical Device Zone, Beichen District, Tianjin, the PRC (“Tasgen”).

 (Genexine and Tasgen are jointly referred hereinafter as the “Parties” and individually as a
“Party”.) 
 WHEREAS 
  

	(A)	 Genexine and Tasgen will be parties to a Capital Increase Subscription Agreement (the “Subscription
Agreement”). 

  

	(B)	 Genexine and Tasgen have agreed to establish a cooperation relationship with each other, under which Genexine,
as the sole and exclusive owner of all the patents, patent applications, know-hows, data and information (the “Licensed Intellectual Properties”), which relate to the Licensed Products (as defined below) and are limited to those
listed on Exhibit A-1 attached hereto and may be updated from time to time during the term of this Agreement upon mutual consents of the Parties, intends to grant the License (as defined below) of the
Licensed Intellectual Properties to Tasgen so that Tasgen can engage in pre-clinical/clinical development, manufacturing, sale and distribution of the Licensed Products in the Territory (as defined below).
Tasgen intends to accept the License of the Licensed Intellectual Properties from Genexine in accordance with this Agreement. 

  

	(C)	 Genexine, as the sole and exclusive owner of all the patents, patent applications, know-hows, data and
information (the “Assigned Intellectual Properties”, together with the Licensed Intellectual Properties, the “Intellectual Properties”), which relate to the Assigned Products (as defined below, together with the
Licensed Products, the “Products”) and are limited to those listed on Exhibit A-2 attached hereto, intends to sell and assign the Assigned Intellectual Properties to Tasgen so that
Tasgen can engage in pre-clinical/clinical development, manufacturing, sale and distribution of the Assigned Products in the Territory (as defined below). Tasgen intends to purchase the Assigned Intellectual
Properties from Genexine in accordance with this Agreement. 

  
 - 1 - 

 Execution Copy 

 

 NOW IT IS AGREED between the Parties as follows: 

 

	1.	 DEFINITIONS 

  

	1.1	 The following words and expressions shall have the meanings given to them below when used in this Agreement:

 “Affiliate” means, with regard to a given natural or legal person (a “Person”), a
Person that controls, is controlled by or is under common control with the given Person. For the purposes of this Agreement, except as otherwise expressly provided, when used with respect to any Person, “control” means the power to
direct the management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise. 

“Assigned Products” means long-acting GLP-1 named as
GX-G6 (“GX-G6”). For the avoidance of doubt, the term “Assigned Products” does not include hyFc Platforms. 

“hyFc Platform” means: as defined in the PRC patent 201410851771, through the fusion of Fc fragment of IgG4 with the amino
acid sequence of target protein, the 231st to 240th amino acid will be replaced by CH2 area of IgD, as a result of which a long-acting medicine, the half-life of which is longer than target protein, is formed. Such fusion protein only has FcRn locus
instead of Fcy Rs binding locus, which avoids cytolysis and immunogenicity. HyFc Platform means such Fc structure of IgD/IgG4. 

“Improvements” means any improvement, modification or alteration to the Licensed Products, Assigned Products, or to the
Intellectual Properties. 
 “Licensed Products” means (i) long-acting human growth hormone named as GX-H9 (“GX-H9”), (ii) long-acting human G-CSF named as GX-G3 (“GX-G3”), (iii) long-acting GLP-2, named as GX-G8 (“GX-G8”), (v) PD-L1 HyFc, named as GX-P2 (“GX- P2”), and (iv) any other products as agreed by the Parties from time to time
after the execution of this Agreement, including but not limited to one product to be mutually agreed by the Parties in good faith within twelve (12) months after the execution of this Agreement, which are developed by using the hyFc Platform
and manufactured by utilizing or embodying the Licensed Intellectual Properties. For the avoidance of doubt, the term “Licensed Products” does not include hyFc Platforms. 

  
 - 2 - 

 Execution Copy 

 

 “Net Sales” means, the gross amount invoiced by Tasgen, and its Affiliates
and sub-licensees to unrelated third parties for sales of the Products in the applicable Territory, less the following deductions to the extent included in the gross invoiced sales price for the Products or
otherwise directly paid or incurred by Tasgen, and its Affiliates and sub-licensees, with respect to sales of the Products in the applicable Territory: 

 

	 	a)	 Trade, quantity and cash discounts allowed; 

 

	 	b)	 Discounts, refunds, rebates, chargebacks, retroactive price adjustments, and any other similar allowances which
effectively reduce the net selling prices (but excluding sales force commissions) in accordance with the PRC GAAP and the laws of the applicable jurisdictions; 

 

	 	c)	 Product returns and allowances; and 

 

	 	d)	 Any value-added taxes imposed on the Product. 

“Territory” means with respect to GX-H9, GX-G6
and GX-G3, the PRC, provided, however, that Tasgen shall have the right to conduct clinic trial in Taiwan and Australia; and with respect to GX-G8 and GX-P2, worldwide. 
 “PRC” means the People’s Republic of China, for the purposes of
this Agreement, excluding Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan. 
 “Technical
Documentation” means complete, correct and effective documents and electronic media embodying the Intellectual Properties furnished to Tasgen by Genexine in accordance with this Agreement, a list of Contents of Technology Transfer is
attached hereto as Exhibit B. 
 “Therapeutic Indication” means (i) treatment of any disease for GX-H9, (ii) treatment of any disease for GX-G6, (iii) treatment of any disease for GX-G3, (iv) with respect to GX-G8, treatment of chemically induced diarrhea (CID), and (v) with respect to GX-P2, treatment of rheumatoid arthritis (RA) and lupus (not including psoriasis). 

 

	1.2	 Any reference in this Agreement to “writing” includes facsimile transmission, telex, cable or
comparable means of communication. 

  

	1.3	 The headings in this Agreement are for convenience only and shall not affect its interpretation.

  

	2.	 ASSIGNMENT AND LICENSE OF INTELLECTUAL PROPERTIES 

 

	 	A.	 ASSIGNMENT. 

  

	2.1	 Subject to the terms and conditions hereof, Genexine hereby agrees to sell, transfer and assign to Tasgen, and
Tasgen agrees to acquire from Genexine, the Assigned Intellectual Properties (the “Assignment”). 

  
 - 3 - 

 Execution Copy 

 

	2.2	 Tasgen shall file the Assignment hereunder with the competent authorities for registration of the change of the
patent applicant within twenty (20) working days after the execution of this Agreement. Genexine shall make commercially reasonable efforts to cooperate with Tasgen in the registration of the change of the patent applicant and the response to
any office action issued to the Assigned Intellectual Properties and shall provide all the documents necessary for the registration. 

  

	2.3	 From the execution date of this Agreement and prior to the effective date of the Assignment, Genexine shall
grant to Tasgen an exclusive (even as to Genexine and its Affiliates) and non-transferable (other than to be transferred to an Affiliate of Tasgen, which has the substantially identical ownership structure as
the then ownership structure of Tasgen) license in the Territory to use and otherwise exploit the Assigned Intellectual Properties and to engage in pre-clinical/clinical development, manufacturing, sale and
distribution of the Assigned Products for the Therapeutic Indication in the Territory. 

  

	 	B.	 LICENSE. 

  

	2.4	 Subject to the terms and conditions hereof, Genexine hereby grants to Tasgen for the term of this Agreement a non-transferable (other than to be transferred to an Affiliate of Tasgen, which has the substantially identical ownership structure as the then ownership structure of Tasgen) license in the Territory to use and
otherwise exploit the Licensed Intellectual Properties to engage in pre-clinical/clinical development, manufacturing, sale and distribution of the Licensed Products for the Therapeutic Indication in the
Territory (the “License”). Genexine hereby grants to Tasgen a right of first negotiation for three (3) years commencing as of the execution of this Agreement, if Genexine decides to grant a license in the PRC to use and
otherwise exploit the relevant Licensed Intellectual Properties of GX-G8 and GX-P2 to engage in pre-clinical/clinical
development, manufacturing, sale and distribution of GX-G8 and GX-P2 for therapeutic indications other than the Therapeutic Indications defined in this Agreement.

  

	2.5	 Tasgen shall use the Licensed Intellectual Properties only in the Territory for
pre-clinical/clinical development, manufacturing, sale, distribution, marketing, and service of the Licensed Products for the Therapeutic Indication only and shall not use the same for any other purpose
without Genexine’s prior written consent. 

  

	2.6	 The License hereunder shall be non-exclusive with respect to the
Licensed Intellectual Properties and exclusive (even as to Genexine and its Affiliates) with respect to the Licensed Products for the Therapeutic Indication in the Territory. For clarity, Genexine has the right to license the Licensed Intellectual
Properties to a third party in the Territory, provided, however, that Tasgen shall be the sole and exclusive licensee in the Territory to use and otherwise exploit the Licensed Intellectual Properties to engage in pre-clinical/clinical development, manufacturing, sale and distribution of the Licensed Products for the Therapeutic Indication. Use of the Licensed Intellectual Properties by Tasgen shall be limited to use for the
licensed activities expressly stipulated in Article 2.5 and further subject to confidentiality restrictions on its use and disclosure as set forth herein. Tasgen shall not perform the licensed activities outside of the Territory. Except as
expressly set forth in this Agreement, nothing in this Agreement shall be deemed to grant, directly or by implication, estoppel or otherwise, any license or rights of any kind to Tasgen. 

  
 - 4 - 

 Execution Copy 

 

	2.7	 Tasgen hereby covenants and agrees that it and its Affiliate shall not, directly or indirectly, develop,
manufacture or sell any Licensed Products outside the Territory. Tasgen shall take reasonable efforts to prevent export of the Licensed Products outside the Territory and to avoid to sell the Licensed Products to a customer who desires to purchase
the Licensed Products for sale outside of the Territory. 

  

	2.8	 Genexine shall not grant any license or rights of any kind in any of the Intellectual Properties to any third
party for the purpose of use, marketing, offer, distribution, sale, research, development or manufacture of the Licensed Products for the Therapeutic Indication in the Territory without Tasgen’s prior written consent. Genexine shall ensure that
neither Genexine nor its Affiliates shall, directly or indirectly, develop, manufacture or sell any Licensed Products or Assigned Products in the Territory. Genexine shall take reasonable efforts to prevent export of the Licensed Products or
Assigned Products from outside the Territory into the Territory and to avoid to sell the Licensed Products or Assigned Products to a customer who desires to purchase the Licensed Products or Assigned Products for sale in the Territory.

  

	2.9	 The License is sublicensable by Tasgen in the Territory, provided that such sublicense (including
have-made right) shall be conditional upon Genexine’s prior written consent (other than to be sublicensed to an Affiliate of Tasgen, which has the substantially identical ownership structure as the then ownership structure of Tasgen), which
consent cannot be unreasonably withheld, and subject to all of the restrictions and obligations of Tasgen set forth herein. 

  

	2.10	 If all or any part of any Intellectual Properties becomes invalid and such invalidity is not due to a breach of
the relevant representations, warranties and covenants made by Genexine in this Agreement, during the term of this Agreement, this Agreement shall remain effective with respect to any other Intellectual Properties that is not invalid. In this event,
during the term of this Agreement, Tasgen continues to be obliged to pay the fees mutually agreed between the Parties pursuant to Article 3.3, 3.4(a) and 3.4(c) of this Agreement in consideration of the License to use the
Intellectual Properties (including know-hows, data and information) as granted hereunder, provided, however, that the royalties pursuant to Article 3.4(b) hereof shall be reduced in accordance with the then market penetration rate of
the relevant Licensed Products in the first year when a biosimilar product is sold in the Territory. 

  

	2.11	 Tasgen shall file the License hereunder with the competent authorities for registration within twenty
(20) working days from the execution of this Agreement. Genexine shall make commercially reasonable efforts to cooperate with Tasgen in the registration and shall provide all the documents necessary for the registration. 

  
 - 5 - 

 Execution Copy 

 

	2.12	 With respect to GX-G8 and GX-P2
related Licensed Products, after completion of first Phase I clinical trial in the Territory, Tasgen will have the right to pursue an out-license to grant a sub-license
(within the scope of License granted to Tasgen hereunder) to a third party for the development and commercialization of the relevant Licensed Product (the “Out-License”).

 Notwithstanding the foregoing, if Tasgen or its sub-licensee fails to submit IND
(investigational new drug) application with respect to GX-G8 or GX-P2 related Licensed Products for any Therapeutic Indication in any jurisdiction within thirty
(30) months after Genexine becomes ready to conduct the technology transfer, subject to a unanimous decision made by all members of the Joint Development Committee, Genexine shall have the right to acquire from Tasgen all the relevant assets
(including without limitation to the rights of intellectual properties) with respect to any such failed Therapeutic Indication of GX-G8 and GX-P2 related Licensed
Products at the cost that Tasgen will have then expended and the license granted to any such failed Therapeutic Indication of GX-G8 and GX-P2 related Licensed Products
will terminate. 
 3. FEES AND ROYALTIES 
  

	3.1	 Upfront Payment for License. As soon as practical but in no event later than (A) ten (10) working
days after the completion of (i) the Closing under the Subscription Agreement, and (ii) other governmental procedures reasonably necessary for the payment under this Article 3.1, or (B) the end of calendar year 2015, whichever
is earlier, Tasgen shall pay US$13,000,000 to Genexine as the upfront license fees in connection with the License. 

  

	3.2	 Payment for Assignment. As soon as practical but in no event later than (A) ten (10) working days
after the completion of (i) the Closing under the Subscription Agreement, and (ii) other governmental procedures reasonably necessary for the payment under this Article 3.2, or (B) the end of calendar year 2015, whichever is
earlier, Tasgen shall pay US$7,000,000 to Genexine as the purchase fee in connection with the Assignment. 

  

	3.3	 Milestone Payments for GX-H9,
GX-G6 and GX-G3. Tasgen shall pay two-time milestone fees per Licensed Product/Assigned Product, as follows, to Genexine
conditioned upon that each Licensed Product/Assigned Product below reaches the following net revenue milestones: 

  

																	
	 Licensed Product

/Assigned Product
	  	Milestone A	 	  	Milestone B	 
	  	Net Sales Target
(US$ million)	 	  	Milestone
Payment
(US$ million)	 	  	Net Sales Target
(US$ million)	 	  	Milestone
Payment
(US$ million)	 
	 GX-H9
	  	 	150	 	  	 	15	 	  	 	250	 	  	 	25	 
	 GX-G6
	  	 	100	 	  	 	10	 	  	 	150	 	  	 	15	 
	 GX-G3
	  	 	50	 	  	 	5	 	  	 	100	 	  	 	10	 

  
 - 6 - 

 Execution Copy 

 

	3.4	 Clinical Milestone Payments, Royalties and Sublicensing Fees for
GX-G8 and GX-P2. 

(a)    Clinical Milestone Payments. Tasgen shall pay clinical milestone fees , as follows, to Genexine conditioned
upon each Licensed Product below reaching the following clinical development milestones: 
  

											
	 Licensed
Product
	  	Indication	  	Milestone A: Initiate
P3 Trials	 	  	Milestone B: approval of
NDA	 
	  	Milestone Payment
(US$ million)	 	  	Milestone Payment
(US$ million)	 
	 GX-P2
	  	RA	  	 	6	 	  	 	10	 
	 GX-P2
	  	Lupus	  	 	3	 	  	 	4	 
	 GX-G8
	  	CID	  	 	1	 	  	 	1	 

 Notwithstanding the foregoing, if Tasgen pursue an Out-License of the out-of-PRC license in accordance with Article 2.12 while reserving the PRC license, provided that the clinical development milestones listed above are achieved
in PRC, the clinical milestone payments shall be reduced to 10% of the total clinical milestone payments indicated above. 

(b)    In the absence of an Out-License pursuant to Article 2.12, Tasgen
shall pay royalties to Genexine in respect of the sales of GX-G8 and GX-P2 related Licensed Products for a term of ten (10) years commencing on the date of first
commercial sale of the relevant Licensed Products, as follows: 
 Annual Net Sales between 0 and US$50,000,000:    6.5%

 Annual Net Sales between US$50,000,000 and US$100,000,000    7.5% 

Annual Net Sales greater than US$100,000,000:    8.5% 

  
 - 7 - 

 Execution Copy 

 

 (c)    Sublicensing Fees. If the development and commercialization
of GX-G8 and GX-P2 related Licensed Products is Out-Licensed in accordance with Article 2.12 hereof, Tasgen shall pay
Genexine a sublicensing fee determined in accordance with the following formula: 
 Genexine’s sublicense fee = X% *
Sublicense Revenue - any paid clinical milestone payments pursuant to Article 3.4(a) hereof. 
 For purpose of the
foregoing formula, “Sublicense Revenue” means any and all licensing fees, royalty and any other income (minus reimbursements and equity purchase) resulting from or in connection with the
Out-License. 
 For purpose of the foregoing formula, “X” shall be
determined in accordance with the following events: 
 (i)    If the
Out-License occurs after the completion of first Phase I clinical trial in the Territory, X shall be 40; 

(ii)    If the Out-License occurs after the start of the first
Phase II clinical trial and prior to the start of the first Phase III, X shall be 30; 
 (iii)    If the Out-License occurs after the start of the first Phase III clinical trial and prior to the first NDA filing, X shall be 15; 

(iv)    If the Out-License occurs after the first NDA filing, X
shall be 10. 
  

	4.	 TRAINING 

  

	4.1	 The Parties shall jointly formulate a training program for Tasgen and shall specify the qualifications of
personnel suitable for receiving such training. Genexine shall provide Tasgen with adequate training in order to enable the personnel of Tasgen having ordinary skill required in the field to manufacture the Licensed Products and Assigned Products in
compliance with the Technical Documentation. Tasgen shall be responsible for expenses relating to travel and lodging (including food) of the personnel sent by Genexine to Tasgen for conducting any training. 

 

	4.2	 In the event that Tasgen encounters technical difficulties that the Parties recognise that Tasgen cannot solve
by itself, Genexine shall, upon request by and on the cost of Tasgen, as soon as is reasonably practicable, but subject to availability, send experts or technical personnel to assist Tasgen in solving such technical problems and applying the
Intellectual Properties in the manufacturing activities of Tasgen. If Genexine does not have its own experts or technical personnel who can solve the technical difficulties, Genexine shall make reasonable efforts to arrange, at Tasgen’s cost,
outside experts or technical personnel suitable for solving the technical difficulties. 

  
 - 8 - 

 Execution Copy 

 

	4.3	 During the term of this Agreement, each Party shall provide reasonable assistance to the other Party in order
to enable the other Party’s personnel to obtain visas and travel permits necessary for the performance of the Contract. 

  

	5.	 JOINT DEVELOPMENT COMMITTEE. 

The Parties shall establish a joint development committee to oversee the development and commercialization activities under this Agreement. The
operating committee shall be composed of three (3) persons, unless jointly agreed otherwise. Genexine shall be entitled to appoint one (1) member and Tasgen shall be entitled to appoint two (2) members who are with appropriate
seniority and functional expertise. 
  

	6.	 IMPROVEMENTS 

  

	6.1	 During the term of this Agreement, if Genexine develops or acquires any Improvements, it shall provide Tasgen
details of the Improvements and such explanations or trainings as Tasgen may request to be able to legally and effectively use the Improvements and grant to Tasgen an exclusive license to use the Improvements free of charge in the Territory. For the
avoidance of any doubt, the scope of Improvements Genexine may provide to Tasgen under this Article is limited to Improvements to the Licensed Products or Assigned Products (e.g., optimization) and does not include Improvements to the hyFc Platform
technology. 

  

	6.2	 During the term of this Agreement, if Tasgen develops or acquires any Improvements, Tasgen shall be the sole
legal owner of the Improvements and has full power, right and authority to grant the license or transfer of ownership of the Improvements. Tasgen shall promptly notify Genexine in writing giving details of the Improvements and shall provide Genexine
with such explanations or trainings to enable Genexine to legally and effectively use the Improvements free of charge and grant to Genexine an exclusive license to use the Improvements free of charge anywhere outside the Territory.

  

	7.	 SALE OF PRODUCTS 

 

	7.1	 The Licensed Products and the Assigned Products which are approved for sale by the relevant regulatory
authority(ies) (e.g., China Food and Drug Administration) may be sold in the Territory and Tasgen shall be responsible for obtaining all necessary regulatory approvals and complying with regulations applicable to the Licensed Products and the
Assigned Products. 

  

	7.2	 During the term of this Agreement Tasgen shall promptly give prior notice to Genexine of sale of the Licensed
Products and the Assigned Products to any customer within the Territory and provide Genexine with copies of purchase order(s) of the customer promptly after receiving the same from the customer. 

  
 - 9 - 

 Execution Copy 

 

	8.	 BOOKS AND RECORDS 

 

	8.1	 Tasgen shall keep complete and proper records and books of account showing the Net Sales, quantity and
description of the Licensed Products and the Assigned Products sold by it, including accounting receipts and monthly and quarterly accounting statements in accordance with the relevant regulations of the PRC. 

 

	8.2	 Such records and books of account shall be kept separate from any books and records which are not related to
the Licensed Products and the Assigned Products and shall be open to inspection by Genexine or its duly authorised representatives or agents. 

  

	8.3	 Tasgen shall permit Genexine (or its representatives) at Genexine’s expense to inspect, audit and
investigate at all reasonable times the books, accounts, records, audit reports, documents and other matters of Tasgen relating to the production and sale of the Licensed Products and Assigned Products. Such inspections, audits and investigations
shall be conducted in such a manner and at such times so as not to adversely affect the operation of Tasgen or the sale of the Licensed Products and the Assigned Products and the results thereof shall be kept confidential. 

 

	9.	 TAX 

Each Party shall (i) bear the cost of all stamp duty, income taxes and duties are legally required to be paid by it as a result of the
transaction contemplated by this Agreement, and (ii) shall comply with all tax reporting and withholding obligations as applicable to it in connection with transactions contemplated by this Agreement as required by all applicable laws. 

 

	10.	 TECHNICAL DOCUMENTATION 

 

	10.1	 Within thirty (30) days after the date of this Agreement, Genexine shall provide Tasgen free of charge
with one set of all Technical Documentation that are reasonably necessary for Tasgen’s use and exploitation of the Intellectual Properties in order to enable Tasgen to perform the licensed activities herein. A list of Contents of Technology
Transfer is attached hereto as Exhibit B. From time to time, Genexine shall provide Tasgen with such requested written or oral explanations thereof at Tasgen’s cost as Tasgen may reasonably require. Further sets of such documents
shall be supplied by Genexine at Tasgen’s expense. 

  

	10.2	 Upon receipt of any such Technical Documentation, Tasgen shall promptly deliver to Genexine a written
acknowledgment of receipt thereof and shall comply with the confidentiality provisions in this Agreement to protect the confidentiality of such Technical Documentation. 

  
 - 10 - 

 Execution Copy 

 

	10.3	 Genexine shall use all reasonable endeavours to ensure that the Technical Documentation shall be readable,
complete and accurate. Tasgen shall notify Genexine in writing within three (3) months after receipt thereof if any of the Technical Documentation is not readable, complete or accurate and Genexine shall correct or replace the defective
portions of the Technical Documentation free of charge to Tasgen. In the absence of a written notice from Tasgen to Genexine within the three (3) months period, the Technical Documentation in question shall be deemed to have been approved and
accepted by Tasgen. 

  

	10.4	 Genexine shall have the right to make necessary amendments to the Technical Documentation and shall provide
Tasgen with such amendments from time to time. 

  

	11.	 MATERIALS 

Tasgen may source raw materials, ingredients and other components for the production of the Licensed Products and the Assigned Products by
itself, provided that the manufacturing of the Licensed Products by using these raw materials, ingredients and components shall meet the technical specifications and standards of Genexine. 

 

	12.	 CONFIDENTIALITY 

 

	12.1	 Tasgen shall, during the term of this Agreement and after its termination or expiration for any reason, keep
confidential and not make use of for any purpose other than the performance of its obligations under this Agreement, nor disclose to any other person otherwise than in accordance with Article 12.2 or with the prior written consent of
Genexine, anything of the Intellectual Properties, including but not limited to, information contained in the Technical Documentation, Improvements and any other information disclosed (whether in writing, verbally or by other means) by or on behalf
of Genexine. Without prejudice to the generality of this obligation above, Tasgen shall: 

  

	 	12.1.1	 keep any and all of the Intellectual Properties separate from its own information or documentation;

  

	 	12.1.2	 arrange proper and secure storage facilities for the Intellectual Properties and control and supervise access
of its employees and personnel to such facilities; 

  

	 	12.1.3	 mark and label all information contained in the Intellectual Properties and Technical Documentation relating to
the Intellectual Properties “confidential”; 

  

	 	12.1.4	 disclose the Intellectual Properties only to its employees pursuant to Article 12.3;

  

	 	12.1.5	 prevent unauthorized access to or disclosure of the Intellectual Properties; and 

 

	 	12.1.6	 not use, reproduce, transform or store any of the Intellectual Properties in any place that is externally
accessible, whether it is in hardcopy or electronic form. 

  
 - 11 - 

 Execution Copy 

 

	 	12.2	 The foregoing obligations of non-use and
non-disclosure shall not apply to: 

  

	 	12.2.1	 information available to the public at the time when it is obtained or which subsequently becomes available to
the public through no fault of Tasgen; 

  

	 	12.2.2	 information which Tasgen can demonstrate was in its possession, as evidenced by written documents, at the time
when it obtains such information from Genexine; 

  

	 	12.2.3	 information properly conveyed to Tasgen after the disclosure by an independent and unrelated third party,
which, third party disclosure was not under an obligation of confidentiality at the time of disclosure of the third party information; and 

  

	 	12.2.4	 information required to be disclosed by law, provided that Tasgen promptly notifies Genexine of such
requirement to enable Genexine the opportunity to oppose such requirement. 

  

	12.3	 During the term of this Agreement Tasgen may disclose information which is confidential under Article
12.1 to its officers, directors, managers and employees, but only to the extent necessary for the purposes of this Agreement and provided such person has signed a confidentiality contract, in the form and substance satisfactory to the board of
the directors of Tasgen. 

  

	12.4	 Tasgen shall, at its own expense, take such steps as Genexine may require to enforce the terms of any
confidentiality contract executed pursuant to Article 12.3 including, but not limited to, the initiation, prosecution and enforcement of any legal proceedings. 

 

	13.	 CLAIMS AND INFRINGEMENTS 

 

	13.1	 Tasgen shall immediately notify Genexine of any claim, or any fact which may lead to a claim, of any nature by
a third party that the use of the Licensed Intellectual Properties by Tasgen is or may be an infringement of a patent or other proprietary right of such third party, but shall take no action relating to such claim or infringement without
Genexine’s written consent. Genexine shall advise Tasgen whether it wishes to conduct a defense of any such claim. Should Genexine elect to conduct such a defense, it shall do so at its own expense, and Genexine shall have sole control of such
defense either in its own name or in the name of Tasgen, as the case may be, and Tasgen shall give all reasonable assistance to Genexine to enable it to do so. 

 

	13.2	 Genexine shall indemnify Tasgen and bear related costs for any claims, losses, damages, proceedings sustained
by Tasgen in relation to any claims that may be made against Tasgen pursuant to Article 13.1, unless such claims, losses, damages, proceedings result from the default by Tasgen of its obligations under this Agreement or the use of Licensed
Intellectual Properties by Tasgen otherwise than in accordance with this Agreement. Notwithstanding the above, the total and aggregate liability of Genexine shall not exceed an amount equal to the sum of (i) the upfront payment received by
Genexine pursuant to Articles 3.1 and 3.2, (ii) any milestone payments of any corresponding product actually received by Genexine pursuant to Article 3.3 and 3.4, and (iii) any other payments received by Genexine
pursuant to this Agreement. 

  
 - 12 - 

 Execution Copy 

 

	13.3	 Tasgen shall immediately notify Genexine of any information it obtains that any third party is or may be
infringing the rights of Genexine relating to the Licensed Intellectual Properties, but shall take no action relating to such infringement without Genexine’s written consent. Genexine shall advise Tasgen whether it wishes to take action with
respect to such infringement. Should Genexine elect to take action with respect to such infringement, it shall do so at its own expense, and Genexine shall have sole control of such action and Tasgen shall give Genexine all reasonable assistance to
enable it to do so. All compensation which may be recovered shall be made to Genexine. 

  

	13.4	 In the event that Genexine elects not to take action under Article 13.3, Tasgen may, with the written
consent of Genexine, take action in relation to the relevant infringement at its own cost and expense, and Genexine shall give all reasonable assistance in connection therewith. All compensation which may be recovered shall be made to Tasgen.
Notwithstanding the foregoing, Tasgen shall not enter into any compromise, settlement or agreement with any person or entities relating to the Licensed Intellectual Properties otherwise than with the written consent of Genexine.

  

	13.5	 Except as provided in this Agreement, Genexine shall have no responsibility for any claim with respect to
licensed activities performed and the Licensed Products or Assigned Products manufactured or distributed by Tasgen hereunder or arising from the use by Tasgen of the Intellectual Properties furnished by Genexine hereunder. Tasgen shall hold harmless
and indemnify Genexine against any claim, loss or damage arising from claims by any third party with respect to any licensed activities performed and the Licensed Products or Assigned Products manufactured or distributed by Tasgen hereunder unless
such claim, loss or damage arises from or is attributable to the any of the representations, warranties or covenants of Genexine herein. In addition, in the event of technical problems of a Licensed Product or Assigned Products as a consequence of
any breach of warranty by Tasgen (including as a result of any failure by Tasgen to correctly apply any Intellectual Properties utilized by Tasgen for such Licensed Product or Assigned Products), Genexine may require Tasgen to implement any
necessary preventive and corrective measures and Tasgen shall comply with Genexine’s advice as soon as reasonably practicable at Tasgen’s own expense. 

 

	13.6	 Notwithstanding anything to the contrary in this Article 13 or elsewhere in this Agreement, neither Party shall
have any liability, whether arising in contract, tort (including negligence), strict liability, breach of warranty or any other theory of law, for any special, incidental, indirect or consequential loss or damage of any nature suffered by the other
Party. 

  
 - 13 - 

 Execution Copy 

 

	14.	 REPRESENTATIONS, WARRANTIES AND COVENANTS 

 

	14.1	 Genexine hereby represents and warrants to Tasgen, that Genexine is the sole legal owner of the Intellectual
Properties and has full power, right and authority to grant the license to or make the assignment to Tasgen pursuant to this Agreement and, to the knowledge of Genexine, any of the Intellectual Properties is free of liens, pledges or any other
encumbrances. To the knowledge of Genexine, there are no claims or investigations pending or threatened against any of the Intellectual Properties. To the knowledge of Genexine, the license and assignment hereunder does not violate the relevant laws
of the respective places of registration of the Parties or infringe any third party rights. To the knowledge of Genexine, the manufacture, use and sale of the Products will not infringe upon the intellectual property rights of any third party in the
Territory. To the knowledge of Genexine, the patents related to GX-G6 and GX-G8 in the Territory should be able to provide protection for the relevant products. The
Licensed Intellectual Properties, and the relevant technical assistance, guidance and training, shall be sufficient to enable Tasgen to perform the licensed activities in accordance with all applicable specifications set forth in the Technical
Documentation. During the term of this Agreement, Genexine shall maintain and protect the validity of the Licensed Intellectual Properties to the greatest extent permitted by the applicable laws. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, THERE
ARE NO EXPRESS OR IMPLIED WARRANTIES, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, RESPECTING THIS AGREEMENT OR ANY INTELLECTUAL PROPERTIES OR TECHNICAL DOCUMENTATION FURNISHED HEREUNDER BY GENEXINE.

  

	14.2	 Except as provided in this Agreement, nothing in this Agreement shall limit the rights of Genexine to use the
Licensed Intellectual Properties anywhere in the world and Tasgen waives and disclaims any right or interest in the Licensed Intellectual Properties which may arise under any law or legal theory out of the permitted use hereunder.

  

	14.3	 Nothing in this Agreement shall: 

 

	 	14.3.1	 constitute a sale, transfer or assignment of the Licensed Intellectual Properties to Tasgen, unless it is
otherwise agreed in other agreements, contracts or arrangements; 

  

	 	14.3.2	 give Tasgen any right, title or interest in or to the Licensed Intellectual Properties except the license to
use in accordance with this Agreement; 

  

	 	14.3.3	 give Tasgen any right to register or apply for registration of any of the Licensed Intellectual Properties
(except this Agreement itself), whether in the PRC or elsewhere; or 

  
 - 14 - 

 Execution Copy 

 

	 	14.3.4	 diminish or affect the rights of Genexine to take legal action or obtain any other relief against any infringer
of the Licensed Intellectual Properties in the PRC or elsewhere. 

  

	14.4	 Tasgen agrees that it shall: 

 

	 	14.4.1	 not register or make any application to register the Licensed Intellectual Properties or any part thereof in
the name of Tasgen in the PRC or elsewhere, whether for copyright, patent right or any other registerable right (for avoidance of doubt, Tasgen is permitted to register the License granted hereunder pursuant to Article 2.11);

  

	 	14.4.2	 strictly adhere to all instructions or advice from Genexine regarding the use of the Licensed Intellectual
Properties; 

  

	 	14.4.3	 comply with intellectual property laws of PRC and each of the jurisdictions where the Licensed Products are
sold by Tasgen with respect to the use of the Licensed Intellectual Properties in such jurisdictions in order to preserve and maintain Genexine’s rights in the Licensed Intellectual Properties; 

 

	 	14.4.4	 inform Genexine of the imposition of any new laws or regulations or changes in laws or regulations imposed in
the PRC during the term of this Agreement which affect performance by either Tasgen or Genexine under this Agreement; 

  

	 	14.4.5	 maintain and protect the validity of the Assigned Intellectual Properties to the greatest extent permitted by
the applicable laws and shall not assign the Assigned Intellectual Properties to its Affiliate (other than to an Affiliate of Tasgen, which has the substantially identical ownership structure as the then ownership structure of Tasgen) or any third
party without Genexine’s prior written consent; and 

  

	 	14.4.6	 not contest, infringe or harm any right which Genexine or any affiliate of Genexine may have in Licensed
Intellectual Properties, whether in the PRC or elsewhere. 

  

	15.	 TERM AND TERMINATION 

 

	15.1	 This Agreement shall take effect upon execution by the Parties and shall remain in full force and effect for 30
years unless terminated earlier pursuant to this Agreement, except that termination shall not affect: 

  

	 	(a)	 the accrued rights and obligations of the Parties at the date of termination; and 

 

	 	(b)	 the continued existence and validity of the rights and obligations of the Parties under those articles which
are designed to survive termination and any provisions of this Agreement necessary for the interpretation or enforcement of this Agreement. 

  
 - 15 - 

 Execution Copy 

 

	15.2	 Unless otherwise provided herein, this Agreement may be terminated: 

 

	 	15.2.1	 by either Party giving notice to the other Party if the other Party has committed a material breach of this
Agreement and such breach, if capable of remedy, has not been so remedied within sixty (60) days following receipt of such notice, unless otherwise provided herein; 

 

	 	15.2.2	 by either Party giving notice to the other Party in the event that an event of Force Majeure continues for a
period of six (6) consecutive months that causes Tasgen to cease the production and sale of the Licensed Products and the Parties have been unable to find an equitable solution pursuant to Article 19; 

 

	 	15.2.3	 by either Party giving notice to the other Party if at any time during the term of this Agreement, the
Government of the PRC should require any material alteration or modification of the contractual rights or obligations of the Parties pursuant to this Agreement which has the effect of preventing the Parties from achieving their business objectives;

  

	 	15.2.4	 by either Party giving notice to the other Party if the other Party becomes bankrupt, or insolvent, or is the
subject of proceedings or arrangements for liquidation or dissolution, or ceases to carry on business, or becomes unable to pay its debts as they become due; 

  

	 	15.2.5	 by Genexine giving notice to Tasgen if Tasgen fails to obtain regulatory approvals or other registrations
necessary for sale or distribution of the Licensed Products in the Territory in accordance with a business plan and timeline approved by the board of the directors of Tasgen from time to time due to a reason attributable to Tasgen or ceases to
pursue clinical development or product registration or to conduct licensed activities in a reasonable scale pursuant to a written resolution made by Tasgen’s board of directors; or 

 

	 	15.2.6	 by either Party giving notice to the other Party if at any time during the term of this Agreement, the
Subscription Agreement or the Joint Venture Agreement is terminated for any reason. However, if the Subscription Agreement or the Joint Venture Agreement is terminated due to a Party’s material breach, such breaching Party will not have the
terminating right under this Article 15.2.6. 

  

	15.3	 Upon termination of this Agreement for whatever reason, Tasgen shall immediately cease to use the Licensed
Intellectual Properties as provided by Genexine and shall cease to manufacture the Licensed Products. Tasgen shall cooperate with Genexine in de- registration of the License hereunder with the competent
authorities. 

  
 - 16 - 

 Execution Copy 

 

	15.4	 Upon termination of this Agreement for whatever reason, Tasgen shall sell to Genexine at market price all the
Licensed Products or parts thereof (which are in good condition for sale to customers and already approved for sale by the China Food and Drug Administration) which are not subject to delivery under a sale to customers. 

 

	15.5	 Upon expiration or termination of this Agreement, all amounts then due and unpaid to Genexine by Tasgen
hereunder, as well as all other amounts accrued but not yet payable to Genexine by Tasgen, shall forthwith become due and payable by Tasgen to Genexine. However, in the event that this Agreement is terminated by Tasgen as a result of Genexine’s
material breach of this Agreement and Tasgen has raised claims against Genexine due to such breach, the aforesaid payment will be suspended until settlement of such claims pursuant to Article 19 hereof. 

 

	15.6	 All Licensed Intellectual Properties, including the Improvements and the Technical Documentation relating to
the Licensed Intellectual Properties as provided by Genexine, recorded in any material form including but not limited to any written records shall be returned by Tasgen to Genexine forthwith upon the termination or expiration of this Agreement.
Tasgen agrees on behalf of itself and its employees that no copies of the Licensed Intellectual Properties in any material form or of the Technical Documentation relating to the Licensed Intellectual Properties shall be made or retained upon and
after the termination or expiration of this Agreement. 

  

	15.7	 Upon termination of this Agreement pursuant to Article Error! Reference source not found., all
Assigned Intellectual Properties, including the Improvements and the Technical Documentation relating to the Assigned Intellectual Properties as provided by Genexine, shall be returned or re-assigned by Tasgen
to Genexine forthwith. Tasgen agrees on behalf of itself and its employees that no copies of the Assigned Intellectual Properties in any material form or of the Technical Documentation relating to the Assigned Intellectual Properties shall be made
or retained upon and after the termination of this Agreement. 

  

	15.8	 Upon termination, Tasgen agrees to permit Genexine and its representatives to inspect the records and accounts
of Tasgen and to investigate generally all business transactions carried on by Tasgen under and pursuant to this Agreement for a period of twelve (12) months following the last sale of the Licensed Products, and Tasgen agrees not to destroy any
of such records prior to the expiration of such twelve (12) month period. 

  

	16.	 INDEPENDENT CONTRACTORS 

The Parties are independent contractors, and nothing in this Agreement shall be construed to constitute either Party to be the agent, partner,
legal representative, attorney or employee of the other for any reason whatsoever. Neither Party shall have the power or authority to bind the other except as specifically set out in this Agreement. 

  
 - 17 - 

 Execution Copy 

 

	17.	 FORCE MAJEURE 

 

	17.1	 “Force Majeure” means all events which are beyond the control of the Parties to this
Agreement, and which are unforeseen, or if foreseen, unavoidable, and which prevent total or partial performance by either Party. Such events shall include but are not limited to any lockouts, explosions, shipwrecks, acts of nature or the public
enemy, fires, flood, sabotage, accidents, strikes, wars, riots, insurrections, and any other similar contingency. 

  

	17.2	 If an event of Force Majeure occurs, to the extent that any contractual obligation of either Party cannot be
performed as a result of such event, such contractual obligation shall be suspended while the Force Majeure subsists and the due date for performance thereof shall be automatically extended, without penalty, for a period equal to such suspension.

  

	17.3	 The Party encountering Force Majeure shall, within fifteen (15) days of the relevant event, notify the
other Party and furnish valid proof of the occurrence of such Force Majeure. Within a reasonable period thereafter that Party shall provide the other Party with evidence of the Force Majeure issued by a relevant agency. The Party encountering Force
Majeure shall also use all reasonable endeavours to minimize the consequences of such Force Majeure. 

  

	17.4	 In the event of Force Majeure, the Parties shall immediately consult with each other in order to mutually agree
an equitable solution (which may involve early termination of this Agreement a part thereof or extension of the term of this Agreement) and shall use all reasonable endeavours to minimize the consequences of such Force Majeure.

  

	18.	 LIABILITY FOR BREACH AND INDEMNIFICATION 

 

	18.1	 Tasgen shall indemnify and hold Genexine harmless against all losses, liabilities, costs, claims, actions,
damages, expenses or demands, which Genexine may incur, or which may be made against Genexine as a result of or in relation to any breach by Tasgen of its obligations under this Agreement or arising out of any improper use of the Licensed
Intellectual Properties by Tasgen. 

  

	18.2	 Genexine shall indemnify and hold Tasgen harmless against all losses, liabilities, costs, claims, actions,
damages, expenses or demands, which Tasgen may incur, or which may be made against Tasgen as a result of or in relation to any breach by Genexine of its obligations under this Agreement, including but not limited to any breach of Genexine’s
representations, warranties and covenants made in Article 14.1. Notwithstanding the above, the total and aggregate liability of Genexine under this Agreement shall not exceed an amount equal to the sum of (i) the upfront payment received
by Genexine pursuant to Articles 3.1 and 3.2, (ii) any payments of any corresponding product actually received by Genexine pursuant to Article 3.3 and 3.4, and (iii) any other payments received by Genexine pursuant
to this Agreement. 

  
 - 18 - 

 Execution Copy 

 

	19.	 SETTLEMENT OF DISPUTES 

Dispute resolution mechanism set forth in the Subscription Agreement shall apply mutatis mutandis. 

 

	20.	 ASSIGNMENT 

  

	20.1	 Neither party may assign or otherwise transfer its rights or obligations under this Agreement without the prior
written consent of the other party, except Genexine shall be entitled to assign or transfer its rights and obligations under this Agreement to any of its Affiliates or to any company which succeeds to the business of Genexine, whether through stock
or asset sale, merger, reorganization or otherwise, provided that Tasgen shall be notified by Genexine of such assignment or transfer in writing and such successor succeeds to Genexine’s rights in the Licensed Intellectual Properties and shall
agree in writing to assume the rights and obligations of Genexine under this Agreement. 

  

	20.2	 This Agreement is binding upon and is made for the benefit of the Parties and their successors and permitted
assignees. 

  

	20.3	 Tasgen shall continue to be bound by the rights and obligations under this Agreement regardless of any change
of control in Tasgen whether through stock or asset sale, merger, reorganization or otherwise and promptly notify Genexine of such change of control in writing. 

 

	21.	 NOTICES 

Any notices to be given under this Agreement shall be in writing and deemed delivered when received by the Party to whom it is addressed, and
receipt shall be evidenced by (i) the written receipt of the receiving Party or the affidavit from the delivering person, if hand delivered, confirming delivery or refusal of delivery by the addressee, (ii) the signed returned receipt or
other written proof of delivery if delivered by registered air or express mail (return receipt requested) or by an internationally recognized courier service, or (iii) electronic proof of transmission if sent by
e-mail, fax or telex, provided that any notice sent by e-mail, fax or telex shall also be sent by registered air or express mail (return receipt requested) or
internationally recognized courier service. Notices shall be given to the relevant party at the addresses set forth below: 
 Tasgen:

 *** 
 Attention: General
Manager 
 E-mail: 

  
 - 19 - 

 Execution Copy 

 

 Genexine: 

*** 
 Attention: *** 

E-mail: *** 
  

	22.	 MISCELLANEOUS 

 

	22.1	 Tasgen shall observe and comply with all laws, rules and regulations applicable to the manufacture, packaging,
storage, handling, advertising, marketing and sale of the Licensed Products in the Territory. Tasgen shall, at its own cost and expense, secure and maintain all necessary governmental permits, licenses and approvals, and will fulfil all other
requirements and undertakings related to this Agreement which are or may become necessary under any law or regulation, to enable the Parties to exercise, enforce and enjoy all of the rights and obligations contained in this Agreement.

  

	22.2	 Failure or delay on the part of either Party to exercise any right, power or privilege hereunder, or any other
contract relating hereto, shall not operate as a waiver thereof, nor shall the partial exercise of any right, power or privilege preclude any other future full and complete exercise thereof. 

 

	22.3	 The validity, interpretation and implementation of this Agreement shall be governed by and construed in
accordance with the laws of the PRC. 

  

	22.4	 This Agreement is written in Chinese and English. If there should be any discrepancy between the English and
Chinese versions of the Agreement, the English version shall be controlling in all respects. 

  

	22.5	 Should any Article or any part of any Article contained in this Agreement be declared invalid or unenforceable
for any reason whatsoever, all other Articles or parts of Articles contained in this Agreement shall remain in full force and effect. 

  

	22.6	 This Agreement and all documentation executed in connection therewith shall constitute the entire agreement
between the Parties with respect to the subject matter and shall automatically cancel and supersede any and all prior or contemporaneous oral or written understandings with respect thereto. In the event of any inconsistency between the Subscription
Agreement, Sino-Foreign Equity Joint Venture Contract dated October 16th, 2015 and this Agreement in relation to the subject matter of this Agreement, this Agreement shall prevail.

  

	22.7	 This Agreement may be amended only by a written instrument signed by the Parties. 

 

	22.8	 This Agreement shall be executed in three (3) originals in English and three (3) in Chinese.

 [The remainder of this page is intentionally left blank] 

  
 - 20 - 

 Execution Copy 

 

 IN WITNESS WHEREOF each of the Parties hereto has caused this Agreement to be executed by its duly
authorised representative on the date first set forth above. 
 TASGEN BIO-TECH (TIANJIN) CO., LTD. GENEXINE,
INC. 
 /s/ TASGEN BIO-TECH (TIANJIN) CO., LTD.     /s/ GENEXINE, INC.

  
 - 21 - 

 Execution Copy 

 

 EXHIBIT A-1 

LIST OF LICENSED INTELLECTUAL PROPERTIES 

[***] 

  
 - 22 - 

 Execution Copy 

 

 EXHIBIT A-2 

LIST OF ASSIGNED INTELLECTUAL PROPERTIES 

[***] 

  
 - 23 - 

 Execution Copy 

 

 EXHIBIT B 

CONTENTS OF TECHNOLOGY TRANSFER 

[***] 

  
 - 24 -EX-10.15

 Exhibit 10.15 

GENEXINE, INC. 
 AND

 I-MAB 

 
  

INTELLECTUAL PROPERTY LICENSE 

AGREEMENT 
  

 
 DATED DECEMBER
22, 2017 

 INTELLECTUAL PROPERTY LICENSE AGREEMENT 

THIS INTELLECTUAL PROPERTY LICENSE AGREEMENT (the “Agreement”) is made on December 22, 2017 

BETWEEN 
  

	(1)	 GENEXINE, INC., a limited liability company established in Korea, with its registered address at ***
(“Genexine”); and 

  

	(2)	 I-MAB, a company established in the laws of Cayman Islands, with
its registered address at *** (“I-Mab”). 

 (Genexine and I-Mab are jointly referred hereinafter as the “Parties” and individually as a “Party”.) 

WHEREAS 
 Genexine and I-Mab have agreed to establish a cooperation relationship with each other, under which Genexine, as the sole and exclusive owner of all the patents, patent applications, know-hows, data and information (the
“Licensed Intellectual Properties”), which relate to the Licensed Product (as defined below) and are limited to those listed on Exhibit A attached hereto and may be updated from time to time during the term of this
Agreement upon mutual consents of the Parties, intends to grant the License (as defined below) of the Licensed Intellectual Properties to I-Mab so that I-Mab can engage
in pre-clinical/clinical development, manufacturing, sale and distribution of the Licensed Product in the Territory (as defined below). I-Mab intends to accept the
License of the Licensed Intellectual Properties from Genexine in accordance with this Agreement. 
 NOW IT IS AGREED between the Parties as follows:

  

	1.	 DEFINITIONS 

  

	 	1.1	 The following words and expressions shall have the meanings given to them below when used in this Agreement:

 “Affiliate” means with regard to a given natural or legal person (a “Person”), a
Person that controls, is controlled by or is under common control with the given Person. For the purposes of this Agreement, except as otherwise expressly provided, when used with respect to any Person, “control” means the power to
direct the management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise. 

  
 - 1 - 

 “Competing Product” means any pharmaceutical product that contains GX-I7 or Hyleukin covered by valid claims of the Hyleukin Patents listed in Exhibit A or any Improvements developed or acquired by Genexine or I-Mab during the term of
this Agreement. 
 “First Commercial Sale” means the first sale of the Licensed Product by
I-Mab, or its Affiliates or sub-licensees to unrelated third parties in any country within the Territory which shall be determined by the delivery date to the party
indicated on the respective invoice for the actual first commercial sale. 
 “hyFc Platform” means the fusion of Fc fragment
which is composed of the human IgD hinge region fused to the N-terminal region of CH2 from IgD, which is in turn fused to the C-terminal region of CH2 and the entire CH3
region of human IgG4. 
 “Improvements” means any improvement, modification or alteration to the Licensed Product,
i.e., GX-I7 or Hyleukin covered by valid claims of the Hyleukin Patents listed in Exhibit A. 

“Licensed Product” means a long-acting (efineptakin alpha – Source: International
Non-proprietary Name) IL-7 cytokine designated as GX-I7 or Hyleukin covered by valid claims of the Hyleukin Patents listed in
Exhibit A. For the avoidance of doubt, the term “Licensed Product” does not include hyFc Platforms. 
 “Net
Sales” means the gross amount invoiced by I-Mab, and its Affiliates and sub-licensees to unrelated third parties for sales of the Licensed Product in the
applicable Territory, less the following deductions to the extent included in the gross invoiced sales price for the Product or otherwise directly paid or incurred by I-Mab, and its Affiliates and sub-licensees, with respect to sales of the Licensed Product in the applicable Territory: 
  

	 	a)	 trade, quantity and cash discounts allowed; 

 

	 	b)	 discounts, refunds, rebates, chargebacks, retroactive price adjustments, and any other similar allowances which
effectively reduce the net selling prices (but excluding sales force commissions) in accordance with PRC GAAP and the laws of the applicable jurisdictions; 

  

	 	c)	 freight expense (actual), including insurance, to the extent it is not charged to or reimbursed by the
customer; 

  

	 	d)	 compulsory payments and rebates directly related to the sale of the Product paid to a governmental authority
pursuant to governmental regulations by reason of any national or local health insurance program or similar program; 

  

	 	e)	 product returns and allowances; and 

 

	 	f)	 taxes (including, VAT, excise, consumption, sales and similar taxes and customs duties) to the extent actually
incurred, paid or collected and remitted to the relevant tax authority (but specifically excluding, for clarity, any income taxes assessed against the income arising from such sale). 

  
 - 2 - 

 “Product Data” means all research data, pharmacology data, preclinical
data, clinical data and/or all regulatory filings and/or other regulatory documentation, information and submissions pertaining to, or made in association with a CTA, new drug application, or marketing approval, for the Licensed Product, resulting
from the development activities conducted by or under the authority of a Party (including, patient report form and other original source data), in each case to the extent controlled by such Party during the term of this Agreement. 

“Territory” means the People’s Republic of China (PRC), Taiwan, Hong Kong and Macau. 

“Technical Documentation” means complete, correct and effective documents and electronic media embodying the Licensed
Intellectual Properties furnished to I-Mab by Genexine in accordance with this Agreement, a list of the Technical Documentation is as attached hereto as Exhibit B. 

“Therapeutic Indication” means treatment of all cancers within the field of Oncology. 

 

	 	1.2	 Any reference in this Agreement to “writing” includes electronic mail, facsimile transmission, telex,
cable or comparable means of communication. 

  

	 	1.3	 The headings in this Agreement are for convenience only and shall not affect its interpretation.

  

	2.	 LICENSE OF INTELLECTUAL PROPERTIES 

 

	 	2.1	 Subject to the terms and conditions hereof, Genexine hereby grants to
I-Mab for the term of this Agreement an exclusive, sublicensable (subject to Article 2.5), transferable (subject to prior written consent of Genexine, such consent shall not be unreasonably withheld)
license in the Territory to use and otherwise exploit the Licensed Intellectual Properties and any Improvements (not including Improvements to the hyFc Platform technology that is not applicable to the Licensed Product) developed or acquired by
Genexine and licensed to I-Mab in accordance with Article 5.1, in connection with the Licensed Product for the Therapeutic Indication (the “License”). 

 

	 	2.2	 The License hereunder shall be limited to engaging in
pre-clinical/clinical development, manufacturing, sale and distribution of the Licensed Product. For clarity, Genexine has the right to license the Platform Patents to a third party in the Territory,
provided, however, that, I-Mab shall be the sole and exclusive licensee in the Territory to use and otherwise exploit the Licensed Intellectual Properties to engage in
pre-clinical/clinical development, manufacturing, sale and distribution of the Licensed Product for the Therapeutic Indication. Use of the Licensed Intellectual Properties by
I-Mab shall be subject to confidentiality restrictions on its use and disclosure as set forth herein. Other than what is necessary to enable I-Mab to perform pre-clinical/clinical development, manufacturing, sale and distribution of the Licensed Product for the Therapeutic Indication within the Territory, I-Mab shall not perform
such licensed activities outside of the Territory without Genexine’s prior written consent. Except as expressly set forth in this Agreement, nothing in this Agreement shall be deemed to grant, directly or by implication, estoppel or otherwise,
any license or rights of any kind to I-Mab. 

  
 - 3 - 

	 	2.3	 I-Mab hereby covenants and agrees that it shall not, directly or
indirectly, develop, manufacture or sell any Licensed Product outside the Territory. I-Mab shall take reasonable efforts to prevent export of the Licensed Product outside the Territory and to avoid selling the
Licensed Product to a customer who desires to purchase the Licensed Product for sale outside of the Territory. 

  

	 	2.4	 Genexine hereby covenants and agrees that it shall not grant any license or rights of any kind in any of the
Licensed Intellectual Properties to any third party for the purpose of use, marketing, offer, distribution, sale, research, development or manufacture of the Licensed Product for the Therapeutic Indication in the Territory without prior
consent of I-Mab. Genexine shall ensure that neither Genexine nor its Affiliates shall, directly or indirectly, develop, manufacture or sell any Licensed Product in the Territory. Genexine shall take
reasonable efforts to prevent export of the Licensed Product from outside the Territory into the Territory and to avoid selling the Licensed Product to a customer who desires to purchase the Licensed Product for sale in the Territory.

  

	 	2.5	 The License is sublicensable by I-Mab in the Territory, provided that
such sublicense (including have-made right) shall require written consent of Genexine, which consent cannot be unreasonably withheld, and subject to all of the restrictions and obligations of I-Mab set forth
herein. Notwithstanding the foregoing, I-Mab may grant sublicenses under the Licensed Intellectual Properties without Genexine’s prior written consent only to
I-Mab’s Affiliates or any third party acting solely as contract manufacturer or contract research organization for I-Mab. For clarity, I-Mab shall be entitled to license its rights in Improvement within the Territory as long as it is not inconsistent with an exclusive license granted to Genexine outside of the Territory. I-Mab shall timely provide all major (including financial) terms of the intended sublicense for Genexine’s review and consideration upon request from Genexine. In any case, all sublicenses shall oblige the
sublicensee to comply with all the terms of this Agreement (except those provisions that, by their clear meaning, are not applicable to a sublicensee), and I-Mab shall remain liable to Genexine for all acts
and omissions of any such sublicensee. I-Mab shall continue to have the payment obligations under this Agreement including milestones and royalties unless the sublicense agreement obliges the sublicensee to
pay milestones and royalties directly to Genexine in which case I-Mab’s milestones and royalties payable under this Agreement will be reduced to the same extent. 

  
 - 4 - 

	 	2.6	 If all or any part of any Licensed Intellectual Properties becomes invalid and such invalidity is not
due to a breach of the relevant representations, warranties and covenants made by Genexine in this Agreement, during the term of this Agreement, this Agreement shall remain effective with respect to any other Licensed Intellectual Properties
that is not invalid. In this event, during the term of this Agreement, I-Mab continues to be obliged to pay the licensing fees mutually agreed between the Parties in this Agreement in consideration of the
License to use the Licensed Intellectual Properties (including know-hows, data and information) as granted hereunder. 

  

	 	2.7	 I-Mab hereby grants to Genexine for the term of this Agreement an
exclusive, sublicensable, royalty free license to use and otherwise exploit any Improvement I-Mab develops and acquires outside the Territory. 

 

	3.	 FEES AND ROYALTIES 

 

	 	3.1	 Payment for License. Within thirty (30) days after the signing of this Agreement, I-Mab shall pay a sum of US$12,000,000 to Genexine as the license fees in connection with the License subject to the terms and conditions provided herein. 

 

	 	3.2	 Development Milestone Payments. I-Mab shall pay development
milestone fees, as follows, to Genexine conditioned upon the Licensed Product reaching the following development milestones within sixty (60) days after each milestone event: 

 

					
	 Milestone
Event
	  	Milestone Payment
	1st	  	First-in-time completion of Phase II Clinical Study in any country in the Territory (i.e. upon submission of the CSR to the relevant regulatory
authority)	  	US$5 million
			
	2nd	  	First-in-time completion of Phase III Clinical Study in any country in the Territory (i.e. upon submission of the CSR to the relevant regulatory
authority)	  	US$8 million
			
	3rd	  	First-in-time receiving of the NDA or BLA approval from the relevant regulatory authority of any country in the Territory with respect to Therapeutic
Indications	  	US$10 million

 * (1) If a milestone event described above in the table will not occur due to cancellation or omission of a
clinical study of any phase, such milestone event shall be deemed reached at the same time as the next milestone event, and the corresponding milestone payment shall be payable when the next milestone payment becomes due. 

  
 - 5 - 

 (2) For clarity, if there are several Therapeutic Indications, I-Mab shall only pay development milestone fees for the first Therapeutic Indication, and I-Mab shall not pay any development milestone fees for the subsequent Therapeutic
Indications in any country in the Territory. 
  

	 	3.3	 Sales Milestone Payments and Royalties. 

(a) Sales Milestone Payments. I-Mab shall pay five-time milestone fees for the Licensed Product,
as follows, to Genexine conditioned upon the Licensed Product reaching the following sales milestones within sixty (60) days after each milestone event: 
  

			
	 Accumulated Net Sales
	  	 Milestone Payment

	US$100 million	  	US$5 million
		
	US$200 million	  	US$20 million
		
	US$500 million	  	US$50 million
		
	US$1000 million	  	US$150 million
		
	US$2000 million	  	US$300 million

 (b) Royalties. I-Mab shall pay a royalty of three percent (3%)
to Genexine in respect of the total annual Net Sales of the Licensed Product during the term of this Agreement defined in Article 15.1. All royalties shall be paid within sixty (60) days after the end of each financial year for the
respective total annual Net Sales of the Licensed Product. 
  

	 	3.4	 Late Payment. 

In the event that I-Mab fails to make payments by the due dates set forth in this Article 3, I-Mab shall pay Genexine a late payment fee amounting to one percent (1%) interest rate per month charged on the amount due for each day of delay. 

 

	 	3.5	 Generic Entry. 

The Development Milestone Payment, Sales Milestone Payment, and Royalties provided in Articles 3.2 and 3.3 shall be reduced by 50%
following the entry of a generic product with respect to the Licensed Product in the Territory without the consent or authorization of I-MAB or any of its sublicensees. 

  
 - 6 - 

	4.	 JOINT DEVELOPMENT COMMITTEE.  

 

	 	4.1	 Within thirty (30) days after the effective date of this Agreement, each Party shall appoint (and notify
the other Party of the identity of) an alliance manager. Each Party may, at any time, replace its alliance manager with another suitably qualified individual, on written notice to the other Party. The alliance managers shall be primarily responsible
for facilitating communications between the Parties and coordinating the Parties’ activities under this Agreement. 

  

	 	4.2	 The Parties shall establish a joint development committee to oversee the development and commercialization
activities, including but not limited to discuss and make decisions with respect to the manufacturing of the Licensed Product for clinical supply in accordance with the I-Mab development plan, under this
Agreement (the “Joint Development Committee” or “JDC”). The Joint Development Committee shall be composed of four members with the equal number of persons from each Party who are with appropriate seniority and
functional expertise. Any decisions of the JDC shall be determined by a majority vote by the JDC members present at a meeting. The minimum quorum for a JDC meeting shall be two-third (2/3) of members who must
be present for the entire meeting. If the JDC cannot reach consensus within two (2) weeks on any issue that comes before the JDC, then the Parties shall immediately refer such matter to the Chief Executive Officers at I-Mab and Genexine for resolution. In the event of a dispute between I-Mab and Genexine that cannot be resolved within two (2) weeks by the Chief Executive Officers with
respect to matters concerning the research and development of Licensed Product, I-Mab shall have the final decision-making authority. Notwithstanding the foregoing,
I-Mab shall have day-to-day operational control over the development, manufacture and commercialization of the Licensed Product,
provided that I-Mab conducts such activities in accordance with the terms and conditions of this Agreement. 

  

	 	4.3	 The JDC shall hold meetings at such times as it elects to do so, but in no event shall such meetings be held
less frequently than once every month. Meetings of the JDC may be held in person, by audio or video teleconference; provided that at least one (1) meeting per year of the JDC shall be held in person.
In-person JDC meetings shall be held at locations selected alternatively by the Parties. Each Party shall be responsible for all of its own expenses of participating in the JDC. No action taken at any meeting
of the JDC shall be effective unless representatives of both Parties are participating. 

  

	 	4.3	 Each Party may from time to time invite a reasonable number of participants, in addition to its
representatives, to attend the JDC meetings in a non-voting capacity; provided that such participants shall be bound by confidentiality and non-use obligations
consistent with the terms of this Agreement and that each Party shall provide prior written notice to the other Party if it has invited any third party (including any consultant) to attend such a meeting. 

  
 - 7 - 

	5.	 IMPROVEMENTS 

  

	 	5.1	 During the term of this Agreement, if Genexine develops or acquires any Improvements, it shall own such
Improvements and provide I-Mab details of the Improvements, whether patentable or not, and grant to I-Mab an exclusive license (with a right to sublicense) to use the
Improvements in the Territory. For the avoidance of any doubt, the scope of Improvements Genexine may license to I-Mab under this Article is limited to Improvements to the Licensed Product and does not include
Improvements to the hyFc Platform technology that is not applicable to the Licensed Product. 

  

	 	5.2	 During the term of this Agreement, if I-Mab develops or acquires any
Improvements, it shall own such Improvements and provide Genexine details of the Improvements, whether patentable or not, and grant to Genexine an exclusive license (with a right to sublicense) to use the Improvements free of charge anywhere outside
the Territory. For the avoidance of any doubt, the scope of Improvements I-Mab may license to Genexine under this Article is limited to Improvements to the Licensed Product and does not include anything that
is not applicable to the Licensed Product. 

  

	 	5.3	 For avoidance of doubt, any use of the Improvements in the Territory by
I-Mab based on Articles 5.1 above shall be subject to the same payment obligations (Sales Milestones and Royalties) as I-Mab is obliged to pay under Article
3.3 with respect to the Licensed Product. 

  

	 	5.4	 If any Improvements developed or acquired by either party are partially or completely funded and/or conducted
by a third party strategic partner, or any third party proprietary information is involved in the studies and/or trials including but not limited to a combination study with other product(s), the Improvements from such studies and/or trials shall
only be shared with the other party subject to the prior written consent of such third party. The party who developed or acquired such Improvements shall make good faith efforts to obtain such prior written consent from such third party to share the
Improvements with the other party. 

  

	6.	 EXCHANGE OF PRODUCT DATA 

 

	 	6.1	 The Parties shall, subject always to approval by the JDC, share with each other the Product Data generated or
attained during the term of this Agreement for use in the product development and commercialization of the Licensed Product within the Territory for I-Mab or outside the Territory for Genexine in English along
with their original language versions if they are not written in English. 

  
 - 8 - 

	 	6.2	 If any such Product Data generated or attained by either party are partially or completely funded and/or
conducted by a third party strategic partner, or any third party proprietary information is involved in the studies and/or trials including but not limited to a combination study with other product(s), the Product Data from such studies and/or
trials shall only be shared with the other party subject to the prior written consent of such third party. The party who generated or attained such Product Data shall make good faith efforts to obtain such prior written consent from such third party
to share the Product Data with the other party. 

  

	7.	 SALE OF LICENSED PRODUCT 

The Licensed Product which is approved for sale by the relevant regulatory authority(ies) (e.g., China Food and Drug Administration (CFDA)) may
be sold in the Territory and I-Mab shall be responsible for obtaining all necessary regulatory approvals and complying with regulations applicable to the Licensed Product. 

 

	8.	 BOOKS AND RECORDS 

 

	 	8.1	 I-Mab shall keep complete and proper records and books of account
showing the Net Sales, quantity and description of the Licensed Product sold by it, including accounting receipts and monthly and quarterly accounting statements in accordance with the relevant regulations of the Territory. 

 

	 	8.2	 Such records and books of account shall be kept separate from any books and records which are not related to
the Licensed Product and shall be open to inspection by Genexine or its duly authorised representatives or agents. 

  

	 	8.3	 I-Mab shall permit Genexine (or its representatives) at Genexine’s
expense to inspect, audit and investigate at all reasonable times the books, accounts, records, audit reports, documents and other matters of I-Mab relating to the production and sale of the Licensed Product.
Such inspections, audits and investigations shall be conducted in such a manner and at such times so as not to adversely affect the operation of I-Mab or the sale of the Licensed Product and the results
thereof shall be kept confidential. Such inspections, audits, and investigations shall be conducted no more often than twice a year, and Genexine should give I-Mab reasonable advance notice prior to conducting
such inspections, audits, and investigations. 

  

	 	8.4	 If any inspection under Article 8.3 reveals an underpayment by
I-Mab of the total amount payable by I-Mab to Genexine hereunder with respect to any period in question for more than 10%, then
I-Mab shall reimburse Genexine for the cost of such audit and pay the deficiency immediately with interest at one percent (1%) per month. 

 

	9.	 TAX 

Each Party shall (i) bear the cost of all stamp duty, income taxes and duties are legally required to be paid by it as a result of the
transaction contemplated by this Agreement, and (ii) shall comply with all tax reporting and withholding obligations as applicable to it in connection with transactions contemplated by this Agreement as required by all applicable laws. 

  
 - 9 - 

	10.	 TECHNICAL DOCUMENTATION 

 

	 	10.1	 Within thirty (30) days after the date of this Agreement, Genexine shall provide I-Mab free of charge with one set of all Technical Documentation that are reasonably necessary for I-Mab’s use and exploitation of the Licensed Intellectual Properties in
order to enable I-Mab to perform the licensed activities herein. A list of the Technical Documentation is attached hereto as Exhibit B. Upon receipt of any such Technical Documentation, I-Mab shall promptly deliver to Genexine a written acknowledgment of receipt thereof and shall comply with the confidentiality provisions in this Agreement to protect the confidentiality of such Technical
Documentation. 

  

	 	10.2	 Genexine shall use all reasonable endeavours to ensure that the Technical Documentation shall be readable,
complete and accurate. I-Mab shall notify Genexine in writing within six (6) months after receipt thereof if any of the Technical Documentation is not readable, complete or accurate and Genexine shall
correct or replace the defective portions of the Technical Documentation free of charge to I-Mab. In the absence of a written notice from I-Mab to Genexine within the
six (6) months period, the Technical Documentation in question shall be deemed to have been approved and accepted by I-Mab. 

 

	11.	 MATERIALS 

I-Mab may source raw materials, ingredients and other components for the production of the Licensed
Product, provided that the manufacturing of the Licensed Product by using these raw materials, ingredients and components shall meet the technical specifications and standards of Genexine. 

 

	12.	 CONFIDENTIALITY 

 

	 	12.1	 I-Mab shall, during the term of this Agreement and after its
termination or expiration for any reason, keep confidential and not make use of for any purpose other than the performance of its obligations under this Agreement, nor disclose to any other person otherwise than in accordance with Article
12.2 or with the prior written consent of Genexine, anything of the Licensed Intellectual Properties, including but not limited to, information contained in the Technical Documentation, Improvements, Product Data and any other information
disclosed (whether in writing, verbally or by other means) by or on behalf of Genexine. Without prejudice to the generality of this obligation above, I-Mab shall: 

 

	 	12.1.1	 identify any and all of the Licensed Intellectual Properties so that it can be distinguished from its own
information or documentation; 

  
 - 10 - 

	 	12.1.2	 arrange proper and secure storage facilities for the Licensed Intellectual Properties and control and supervise
access of its employees and personnel to such facilities; 

  

	 	12.1.3	 mark and label all information contained in the Licensed Intellectual Properties and Technical Documentation
relating to the Licensed Intellectual Properties “confidential”; 

  

	 	12.1.4	 disclose the Licensed Intellectual Properties only to its employees pursuant to Article 12.3;

  

	 	12.1.5	 prevent unauthorized access to or disclosure of the Licensed Intellectual Properties; and

  

	 	12.1.6	 not use, reproduce, transform or store any of the Licensed Intellectual Properties in any place that is
externally accessible, whether it is in hardcopy or electronic form. 

  

	 	12.2	 The foregoing obligations of non-use and
non-disclosure shall not apply to: 

  

	 	12.2.1	 information available to the public at the time when it is obtained or which subsequently becomes available to
the public through no fault of I-Mab; 

  

	 	12.2.2	 information which I-Mab can demonstrate was in its possession, as
evidenced by written documents, at the time when it obtains such information from Genexine; 

  

	 	12.2.3	 information properly conveyed to I-Mab after the disclosure by an
independent and unrelated third party, which, third party disclosure was not under an obligation of confidentiality at the time of disclosure of the third party information; and 

 

	 	12.2.4	 information required to be disclosed by law, provided that I-Mab
promptly notifies Genexine of such requirement to enable Genexine the opportunity to oppose such requirement. 

  

	 	12.3	 During the term of this Agreement I-Mab may disclose information which
is confidential under Article 12.1 to its officers, directors, managers and employees, but only to the extent necessary for the purposes of this Agreement and provided such person has signed a confidentiality contract, in the form and
substance satisfactory to the board of the directors of I-Mab. 

  

	 	12.4	 I-Mab shall, at its own expense, take such steps as Genexine may
require to enforce the terms of any confidentiality contract executed pursuant to Article 12.3 including, but not limited to, the initiation, prosecution and enforcement of any legal proceedings. 

  
 - 11 - 

	13.	 CLAIMS AND INFRINGEMENTS 

 

	 	13.1	 I-Mab shall immediately notify Genexine of any claim, or any fact which
may lead to a claim, of any nature by a third party that the use of the Licensed Intellectual Properties by I-Mab is or may be an infringement of a patent or other proprietary right of such third party, but
shall take no action relating to such claim or infringement without Genexine’s written consent. Genexine shall advise I-Mab whether it wishes to conduct a defense of any such claim. Should Genexine elect
to conduct such a defense, it shall do so at its own expense, and Genexine shall have sole control of such defense either in its own name or in the name of I-Mab, as the case may be, and I-Mab shall give all reasonable assistance to Genexine to enable it to do so. 

  

	 	13.2	 Genexine shall indemnify I-Mab and bear related costs for any claims,
losses, damages, proceedings sustained by I-Mab in relation to any claims that may be made against I-Mab pursuant to Article 13.1, unless such claims, losses,
damages, proceedings result from the default by I-Mab of its obligations under this Agreement or the use of Licensed Intellectual Properties by I-Mab otherwise than in
accordance with this Agreement. Notwithstanding the above, the total and aggregate liability of Genexine shall not exceed an amount equal to the sum of (i) the payment received by Genexine pursuant to Article 3.1, (ii) any milestone
payments actually received by Genexine pursuant to Articles 3.2 and 3.3 and (iii) any other payments received by Genexine pursuant to this Agreement. 

 

	 	13.3	 I-Mab shall immediately notify Genexine of any information it obtains
that any third party is or may be infringing the Platform Patents, but shall take no action relating to such infringement without Genexine’s written consent. Genexine shall advise I-Mab whether it wishes
to take action with respect to such infringement. Should Genexine elect to take action with respect to such infringement, it shall do so at its own expense, and Genexine shall have sole control of such action and
I-Mab shall give Genexine all reasonable assistance to enable it to do so. All compensation which may be recovered shall be made to Genexine. 

 

	 	13.4	 In the event that Genexine elects not to take action under Article 13.3,
I-Mab shall be entitled to take action in relation to the relevant infringement at its own cost and expense, and Genexine shall give all reasonable assistance in connection therewith. All compensation which
may be recovered shall be made to I-Mab. Notwithstanding the foregoing, I-Mab shall not enter into any compromise, settlement or agreement with any person or entities
relating to the Platform Patents otherwise than with the written consent of Genexine. 

  

	 	13.5	 Genexine shall immediately notify I-Mab of any information it obtains
that any third party is or may be infringing the Hyleukin Patents, but shall take no action relating to such infringement without I-Mab’s written consent. I-Mab
shall advise Genexine whether it wishes to take action with respect to such infringement. Should I-Mab elect to take action with respect to such infringement, it shall do so at its own expense, and I-Mab shall have sole control of such action and Genexine shall give I-Mab Genexine all reasonable assistance to enable it to do so. All compensation which may be recovered
shall be made to I-Mab. 

  
 - 12 - 

	 	13.6	 In the event that I-Mab elects not to take action under Article
13.5, Genexine shall be entitled to take action in relation to the relevant infringement at its own cost and expense, and I-Mab shall give all reasonable assistance in connection therewith. All
compensation which may be recovered shall be made to Genexine. Notwithstanding the foregoing, Genexine shall not enter into any compromise, settlement or agreement with any person or entities relating to the Hyleukin Patents otherwise than with the
written consent of I-Mab. 

  

	 	13.7	 Except as provided in this Agreement, Genexine shall have no responsibility for any claim with respect to
licensed activities performed and the Licensed Product manufactured or distributed by I-Mab hereunder or arising from the use by I-Mab of the Licensed Intellectual
Properties furnished by Genexine hereunder. I-Mab shall hold harmless and indemnify Genexine against any claim, loss or damage arising from claims by any third party with respect to any licensed activities
performed and the Licensed Product manufactured or distributed by I-Mab hereunder unless such claim, loss or damage arises from or is attributable to the any of the representations, warranties or covenants of
Genexine herein. In addition, in the event of technical problems of the Licensed Product as a consequence of any breach of warranty by I-Mab (including as a result of any failure by I-Mab to correctly apply any Licensed Intellectual Properties utilized by I-Mab for such Licensed Product), Genexine may require I-Mab
to implement any necessary preventive and corrective measures and I-Mab shall comply with Genexine’s advice as soon as reasonably practicable at I-Mab’s own
expense. 

  

	 	13.8	 Notwithstanding anything to the contrary in this Article 13 or elsewhere in this Agreement, neither
Party shall have any liability, whether arising in contract, tort (including negligence), strict liability, breach of warranty or any other theory of law, for any special, incidental, indirect or consequential loss or damage of any nature suffered
by the other Party. 

  

	14.	 REPRESENTATIONS, WARRANTIES AND COVENANTS 

 

	 	14.1	 Genexine hereby represents and warrants to I-Mab, that Genexine is the
sole legal owner of the Licensed Intellectual Properties and has full power, right and authority to grant the License to I-Mab pursuant to this Agreement in the Territory and, to the knowledge of Genexine, any
of the Licensed Intellectual Properties is free of liens, pledges or any other encumbrances in the Territory. To the knowledge of Genexine, there are no claims or investigations pending or threatened against any of the Licensed Intellectual
Properties in the Territory. To the knowledge of Genexine, the license hereunder, the performance of the licensed activities, and the Licensed Product do not violate the relevant laws of the respective places of registration of the Parties or
infringe any third party rights. The Licensed Intellectual Properties, and the relevant technical assistance, guidance and training, shall be sufficient to enable I-Mab to perform the licensed activities in
accordance with all applicable specifications set forth in the Technical Documentation. During the term of this Agreement, Genexine shall maintain and protect the validity of the Licensed Intellectual Properties to the greatest extent permitted by
the applicable laws. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, THERE ARE NO EXPRESS OR IMPLIED WARRANTIES, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, RESPECTING THIS AGREEMENT OR ANY LICENSED
INTELLECTUAL PROPERTIES OR TECHNICAL DOCUMENTATION FURNISHED HEREUNDER BY GENEXINE. 

  
 - 13 - 

	 	14.2	 Except as provided in this Agreement, nothing in this Agreement shall limit the rights of Genexine to use the
Licensed Intellectual Properties anywhere in the world and I-Mab waives and disclaims any right or interest in the Licensed Intellectual Properties which may arise under any law or legal theory out of the
permitted use hereunder. 

  

	 	14.3	 Nothing in this Agreement shall: 

 

	 	14.3.1	 constitute a sale, transfer or assignment of the Licensed Intellectual Properties to I-Mab, unless it is otherwise agreed in other agreements, contracts or arrangements; 

  

	 	14.3.2	 give I-Mab any right, title or interest in or to the Licensed
Intellectual Properties except the license to use in accordance with this Agreement; 

  

	 	14.3.3	 give I-Mab any right to register or apply for registration of any of
the Licensed Intellectual Properties (except this Agreement itself), whether in the Territory or elsewhere; or 

  

	 	14.3.4	 diminish or affect the rights of Genexine to take legal action or obtain any other relief against any infringer
of the Licensed Intellectual Properties in the Territory or elsewhere. 

  

	 	14.4	 I-Mab agrees that it shall: 

 

	 	14.4.1	 not register or make any application to register the Licensed Intellectual Properties or any part thereof in
the name of I-Mab in the Territory or elsewhere, whether for copyright, patent right or any other registerable right (for avoidance of doubt, I-Mab is permitted to
register the License granted hereunder pursuant to Article 2.9); 

  
 - 14 - 

	 	14.4.2	 strictly adhere to all instructions or advice from Genexine regarding the use of the Licensed Intellectual
Properties; 

  

	 	14.4.3	 comply with intellectual property laws of the Territory and each of the jurisdictions where the Licensed
Products are sold by I-Mab with respect to the use of the Licensed Intellectual Properties in such jurisdictions in order to preserve and maintain Genexine’s rights in the Licensed Intellectual
Properties; 

  

	 	14.4.4	 inform Genexine of the imposition of any new laws or regulations or changes in laws or regulations imposed in
the Territory during the term of this Agreement which affect performance by either I-Mab or Genexine under this Agreement; 

 

	 	14.4.5	 maintain and protect the validity of the Licensed Intellectual Properties to the greatest extent permitted by
the applicable laws and shall not assign the Licensed Intellectual Properties to its Affiliate or any third party without Genexine’s prior written consent; and 

 

	 	14.4.6	 not contest, infringe or harm any right which Genexine or any affiliate of Genexine may have in Licensed
Intellectual Properties, whether in the Territory or elsewhere. 

  

	15.	 TERM AND TERMINATION 

 

	 	15.1	 This Agreement shall take effect upon execution by the Parties and shall, unless otherwise terminated according
to Article 15.2 hereof, remain in full force and effect until the later of (i) the expiry of the last to expire patent specified in Exhibit A as of the date of execution of this Agreement that includes a valid claim for the
Territory and that covers the composition of the Licensed Product or (ii) fifteen (15) years after the First Commercial Sale of the Licensed Product unless terminated earlier pursuant to this Agreement, except that termination shall not affect:

  

	 	(a)	 the accrued rights and obligations of the Parties at the date of termination; and 

 

	 	(b)	 the continued existence and validity of the rights and obligations of the Parties under those articles which
are designed to survive termination and any provisions of this Agreement necessary for the interpretation or enforcement of this Agreement. 

  

	 	15.2	 Unless otherwise provided herein, this Agreement may be terminated: 

 

	 	15.2.1	 by either Party giving notice to the other Party if the other Party has committed a material breach of this
Agreement and such breach, if capable of remedy, has not been so remedied within sixty (60) days following receipt of such notice, unless otherwise provided herein; 

  
 - 15 - 

	 	15.2.2	 by either Party giving notice to the other Party in the event that an event of Force Majeure continues for a
period of six (6) consecutive months that causes I-Mab to cease the production and sale of the Licensed Product and the Parties have been unable to find an equitable solution pursuant to Article
19; 

  

	 	15.2.3	 by either Party giving notice to the other Party if at any time during the term of this Agreement, any
government of the Territory should require any material alteration or modification of the contractual rights or obligations of the Parties pursuant to this Agreement which has the effect of preventing the Parties from achieving their business
objectives; 

  

	 	15.2.4	 by either Party giving notice to the other Party if the other Party becomes bankrupt, or insolvent, or is the
subject of proceedings or arrangements for liquidation or dissolution, or ceases to carry on business, or becomes unable to pay its debts as they become due; 

  

	 	15.2.5	 by Genexine giving notice to I-Mab if
I-Mab fails to use commercial reasonable effort to obtain regulatory approvals or other registrations necessary for sale or distribution of the Licensed Product in the Territory in accordance with a business
plan and timeline approved by the Parties from time to time due to a reason attributable to I-Mab (i.e. due to fault or negligence of I-Mab) or ceases to pursue clinical
development or product registration or to conduct licensed activities in a reasonable scale pursuant to an agreement by the Parties. It is expressly stated that such termination events shall include, among others, (a) the first Development
Milestone specified in Article 3.3(a) fails to be reached within seven (7) years after the signing of this Agreement, (b) the second Development Milestone specified in Article 3.2 fails to be reached within ten
(10) years after the signing of this Agreement and (c) I-Mab fails to commercially launch the Licensed Product in the Territory within twelve (12) years after the signing of this Agreement; or

  

	 	15.2.6	 by mutual agreement of the parties. 

 

	 	15.3	 In case this Agreement is terminated by Genexine pursuant to Articles 15.2.1, 15.2.2, 15.2.4
or 15.2.5, or by I-Mab pursuant to Article 15.2.3, I-Mab shall not, and shall ensure that its Affiliates shall not, develop, manufacture, market, promote,
sell, offer for sale, distribute or otherwise make available (or contract with a third party to do any of the foregoing) any Competing Product for a period of seven (7) years after any such termination. 

 

	 	15.4	 Upon termination of this Agreement for whatever reason, I-Mab shall
immediately cease to use the Licensed Intellectual Properties as provided by Genexine and shall cease to manufacture or sell the Licensed Product. I-Mab shall cooperate with Genexine in de-registration of the License hereunder with the competent authorities. 

  
 - 16 - 

	 	15.5	 Upon termination of this Agreement for whatever reason, Genexine may, at its sole discretion, choose to buy at
I-Mab’s initial purchase price any quantities of the Licensed Product or parts thereof remaining in I-Mab’s inventory (which are in good condition for sale to customers and already approved for sale
by the China Food and Drug Administration which are not subject to delivery under a sale to customers. 

  

	 	15.6	 Upon expiration or termination of this Agreement, all amounts then due and unpaid to Genexine by I-Mab hereunder, as well as all other amounts accrued but not yet payable to Genexine by I-Mab, shall forthwith become due and payable by
I-Mab to Genexine. However, in the event that this Agreement is terminated by I-Mab as a result of Genexine’s material breach of this Agreement and I-Mab has raised claims against Genexine due to such breach, the aforesaid payment will be suspended until settlement of such claims pursuant to Article 19 hereof. 

 

	 	15.7	 All Licensed Intellectual Properties, including the Improvements and the Technical Documentation relating to
the Licensed Intellectual Properties as provided by Genexine, recorded in any material form including but not limited to any written records shall be returned by I-Mab to Genexine forthwith upon the
termination or expiration of this Agreement. I-Mab agrees on behalf of itself and its employees that no copies of the Licensed Intellectual Properties in any material form or of the Technical Documentation
relating to the Licensed Intellectual Properties shall be made or retained upon and after the termination or expiration of this Agreement. 

  

	 	15.8	 Upon termination, I-Mab agrees to permit Genexine and its
representatives to inspect the records and accounts of I-Mab and to investigate generally all business transactions carried on by I-Mab under and pursuant to this
Agreement for a period of twelve (12) months following the last sale of the Licensed Product, and I-Mab agrees not to destroy any of such records prior to the expiration of such twelve (12) month
period. 

  

	16.	 INDEPENDENT CONTRACTORS 

The Parties are independent contractors, and nothing in this Agreement shall be construed to constitute either Party to be the agent, partner,
legal representative, attorney or employee of the other for any reason whatsoever. Neither Party shall have the power or authority to bind the other except as specifically set out in this Agreement. 

 

	17.	 FORCE MAJEURE 

 

	 	17.1	 “Force Majeure” means all events which are beyond the control of the Parties to this
Agreement, and which are unforeseen, or if foreseen, unavoidable, and which prevent total or partial performance by either Party. Such events shall include but are not limited to any lockouts, explosions, shipwrecks, acts of nature or the public
enemy, fires, flood, sabotage, accidents, strikes, wars, riots, insurrections, and any other similar contingency. 

  
 - 17 - 

	 	17.2	 If an event of Force Majeure occurs, to the extent that any contractual obligation of either Party cannot be
performed as a result of such event, such contractual obligation shall be suspended while the Force Majeure subsists and the due date for performance thereof shall be automatically extended, without penalty, for a period equal to such suspension.

  

	 	17.3	 The Party encountering Force Majeure shall, within fifteen (15) days of the relevant event, notify the
other Party and furnish valid proof of the occurrence of such Force Majeure. Within a reasonable period thereafter that Party shall provide the other Party with evidence of the Force Majeure issued by a relevant agency. The Party encountering Force
Majeure shall also use all reasonable endeavours to minimize the consequences of such Force Majeure. 

  

	 	17.4	 In the event of Force Majeure, the Parties shall immediately consult with each other in order to mutually agree
an equitable solution (which may involve early termination of this Agreement a part thereof or extension of the term of this Agreement) and shall use all reasonable endeavours to minimize the consequences of such Force Majeure.

  

	18.	 LIABILITY FOR BREACH AND INDEMNIFICATION 

 

	 	18.1	 I-Mab shall indemnify and hold Genexine harmless against all losses,
liabilities, costs, claims, actions, damages, expenses or demands, which Genexine may incur, or which may be made against Genexine as a result of or in relation to any breach by I-Mab of its obligations under
this Agreement or arising out of any improper use of the Licensed Intellectual Properties by I-Mab. 

  

	 	18.2	 Genexine shall indemnify and hold I-Mab harmless against all losses,
liabilities, costs, claims, actions, damages, expenses or demands, which I-Mab may incur, or which may be made against I-Mab as a result of or in relation to any breach
by Genexine of its obligations under this Agreement, including but not limited to any breach of Genexine’s representations, warranties and covenants made in Article 13.1. Notwithstanding the above, the total and aggregate liability of
Genexine under this Agreement shall not exceed an amount equal to the sum of (i) the payment received by Genexine pursuant to Articles 3.1, (ii) any milestone payments of any corresponding product actually received by Genexine pursuant
to Article 3.2 and 3.3 and (iii) any other payments received by Genexine pursuant to this Agreement. 

  
 - 18 - 

	19.	 SETTLEMENT OF DISPUTES 

All disputes arising out of or in connection with this Agreement shall be submitted to the Singapore Mediation Procedure of the Singapore
Mediation Centre for the time being in force. The Parties agree to participate in the mediation and undertake to abide by the terms of any settlement reached. If contrary to expectation, no amicable settlement can be reached, both Parties hereto
agree to submit to Arbitration under the Rules of the Singapore International Arbitration Centre by one (1) arbitrator appointed in accordance with the said Rules. The arbitrator shall have the authority to grant injunctive relief or other
specific performance. Hearings shall be conducted in English and shall take place in Singapore at Singapore International Arbitration Centre. Notwithstanding any other provision of this Agreement, the Parties may seek an injunctive relief or any
other form of equitable relief in any court of competent jurisdiction. 
  

	20.	 ASSIGNMENT 

  

	 	20.1	 Neither Party may assign or otherwise transfer its rights or obligations under this Agreement without the prior
written consent of the other Party, except Genexine shall be entitled to assign or transfer its rights and obligations under this Agreement to any of its Affiliates or to any third party which succeeds to the business of Genexine, whether through
stock or asset sale, merger, reorganization or otherwise, provided that I-Mab shall be notified by Genexine of such assignment or transfer in writing and such successor succeeds to Genexine’s rights in
the Licensed Intellectual Properties and shall agree in writing to assume the rights and obligations of Genexine under this Agreement. 

  

	 	20.2	 This Agreement is binding upon and is made for the benefit of the Parties and their successors and permitted
assignees. 

  

	 	20.3	 I-Mab shall continue to be bound by the rights and obligations under
this Agreement regardless of any change of control in I-Mab whether through stock or asset sale, merger, reorganization or otherwise and promptly notify Genexine of such change of control in writing.

  

	21.	 NOTICES 

Any notices to be given under this Agreement shall be in writing and deemed delivered when received by the Party to whom it is addressed, and
receipt shall be evidenced by (i) the written receipt of the receiving Party or the affidavit from the delivering person, if hand delivered, confirming delivery or refusal of delivery by the addressee, (ii) the signed returned receipt or
other written proof of delivery if delivered by registered air or express mail (return receipt requested) or by an internationally recognized courier service, or (iii) electronic proof of transmission if sent by fax or telex, provided that any
notice sent by fax or telex shall also be sent by registered air or express mail (return receipt requested) or internationally recognized courier service. Notices shall be given to the relevant Party at the addresses set forth below: 

I-Mab: 

Address: *** 
 Attention: *** 

Telephone: *** 
 Fax: *** 

E-mail: *** 

  
 - 19 - 

 Genexine: 

Address: *** 
 Attention: *** 

Telephone: *** 
 Fax: *** 

E-mail: *** 
  

	22.	 MISCELLANEOUS 

 

	 	22.1	 I-Mab shall observe and comply with all laws, rules and regulations
applicable to the manufacture, packaging, storage, handling, advertising, marketing and sale of the Licensed Product in the Territory. I-Mab shall, at its own cost and expense, secure and maintain all
necessary governmental permits, licenses and approvals, and will fulfil all other requirements and undertakings related to this Agreement which are or may become necessary under any law or regulation, to enable the Parties to exercise, enforce and
enjoy all of the rights and obligations contained in this Agreement. 

  

	 	22.2	 Failure or delay on the part of either Party to exercise any right, power or privilege hereunder, or any other
contract relating hereto, shall not operate as a waiver thereof, nor shall the partial exercise of any right, power or privilege preclude any other future full and complete exercise thereof. 

 

	 	22.3	 The validity, interpretation and implementation of this Agreement shall be governed by and construed in
accordance with the laws of Singapore without regard to its conflict of laws provisions. 

  

	 	22.4	 Should any Article or any part of any Article contained in this Agreement be declared invalid or unenforceable
for any reason whatsoever, all other Articles or parts of Articles contained in this Agreement shall remain in full force and effect. 

  
 - 20 - 

	 	22.5	 This Agreement and all documentation executed in connection therewith shall constitute the entire agreement
between the Parties with respect to the subject matter and shall automatically cancel and supersede any and all prior oral understandings with respect thereto, unless such understandings are memorialized in writing contemporaneous with the signing
of this Agreement. 

  

	 	22.6	 This Agreement may be amended only by a written instrument signed by the Parties. 

 

	 	22.7	 This Agreement shall be executed in two (2) or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. If any signature is delivered by e-mail delivery of a “PDF” format data file, such signature shall create a valid and
binding obligation of the Party executing (or on whose behalf such signature is executed) with the same force and effect as if such “PDF” signature page were an original thereof. 

[The remainder of this page is intentionally left blank] 

  
 - 21 - 

 IN WITNESS WHEREOF each of the Parties hereto has caused this Agreement to be executed by its duly
authorised representative on the date first set forth above. 
  

			
	I-MAB	 	GENEXINE, INC.
	(official chop)	 	
		
	/s/ I-MAB	 	/s/ GENEXINE, INC.

  
 - 22 - 

 EXHIBIT A 

LIST OF LICENSED INTELLECTUAL PROPERTIES 

[***] 

  
 - 23 - 

 EXHIBIT B 

TECHNICAL DOCUMENTATION 

[***] 

  
 - 24 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}]]